|1.||Ohki, Hitoshi: 1 article (01/2009)|
|2.||Shiose, Yoshinobu: 1 article (01/2009)|
|3.||Yamashita, Fumiyoshi: 1 article (01/2009)|
|4.||Kuga, Hiroshi: 1 article (01/2009)|
|5.||Hashida, Mitsuru: 1 article (01/2009)|
|6.||Ikeda, Masahiro: 1 article (01/2009)|
|7.||Kobayashi, To-ru: 1 article (02/2008)|
|8.||Sugahara, Shu-ichi: 1 article (02/2008)|
|9.||Kajiki, Masahiro: 1 article (02/2008)|
|10.||Kuriyama, Hiroshi: 1 article (02/2008)|
01/01/2009 - "CM-Dex-PA-Gly-Gly-Phe-Gly-DXR and CM-Dex-PA-Gly-Gly-Ile-Gly-DXR indicated strong antitumor activity, with the comparable pharmacokinetic profile of released DXR in tumor. "
11/01/1995 - "Compared with DXR, CMPul-DXR conjugates bound through Gly-Gly-Phe-Gly and Gly-Phe-Gly-Gly spacers significantly suppressed the tumor growth, while CMPul-DXR conjugate bound through Gly-Gly-Gly-Gly showed less antitumor effect than DXR. "
02/01/2008 - "AZ10992 is a novel paclitaxel-carboxymethyl (CM) dextran conjugate via a Gly-Gly-Phe-Gly linker with the molecular weight (MW) of 150 kDa. Our previous studies demonstrated that AZ10992 exerts strong antitumor activity against the human tumor xenografts that are highly refractory to paclitaxel, attributable to passive tumor targeting of released paclitaxel. "
|1.||Heterologous Transplantation (Xenotransplantation)